Technology
Health
Biotechnology

Recro Pharma

$6.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-2.34%) Today
-$0.15 (-2.34%) Today

Why Robinhood?

You can buy or sell Recro Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Recro Pharma, Inc. Common Stock, also called Recro Pharma, is a pharmaceutical company, which engages in the research and development of non-opioid therapeutics for the treatment of acute post operative pain. Read More It operates through the Acute Care, and Contract Development and Manufacturing (CDMO) business segment. The Acute Care segment focuses on developing innovative products for hospital and related settings. The CDMO segment leverages the company's formulation expertise to develop and manufacture pharmaceutical products using the company's proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine, and Fadolmidine. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Malvern, PA.

Employees
260
Headquarters
Malvern, Pennsylvania
Founded
2007
Market Cap
139.74M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
245.43K
High Today
$6.44
Low Today
$6.18
Open Price
$6.31
Volume
343.19K
52 Week High
$13.05
52 Week Low
$4.78

Collections

Technology
Health
Biotechnology
Pharmaceutical
Research And Development
Therapy
Manufacturing
2014 IPO

News

MarketWatchMar 25

Recro Pharma's stock plunges to pace premarket decliners after 2nd CRL for pain treatment

Shares of Recro Pharma Inc. REPH, -34.04% plummeted 46% to pace all premarket decliners Monday, after the specialty pharmaceutical company said it received a second "complete response letter" (CRL) from the Food and Drug Administration regarding the new drug application for intravenous meloxicam for the treatment of moderate to severe pain. The comments in the CRL, which was unveiled late Friday, focused on onset and duration, saying the delayed onset failed to meet prescriber expectations for intravenous d...

48
MarketWatchMar 25

Recro Pharma Inc.

Shares of Recro Pharma Inc. plummeted 46% to pace all premarket decliners Monday, after the specialty pharmaceutical company said it received a second "complete response letter" (CRL) from the Food and Drug Administration regarding the new drug application for intravenous meloxicam for the treatment of moderate to severe pain. The comments in the CRL, which was unveiled late Friday, focused on onset and duration, saying the delayed onset failed to meet prescriber expectations for intravenous drugs, and citi...

264
Seeking AlphaMar 22

FDA rejects Recro Pharma's IV meloxicam again

Recro Pharma (REPH +1.2% ) is set for a significant down move after receiving a Complete Response Letter (CRL) from the FDA regarding its marketing application for IV meloxicam, its second.

74

Earnings

-$1.34
-$1.05
-$0.77
-$0.48
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.